<?xml version='1.0' encoding='UTF-8'?>
<Organism_Record>
  <Organism_ID>ASD05660000_1</Organism_ID>
  <Organism>Human</Organism>
  <Organism_Latin>Homo sapiens</Organism_Latin>
  <UniProt_ID>P19793</UniProt_ID>
  <Seq_Length>462</Seq_Length>
  <Molecule_Weight>50811</Molecule_Weight>
  <KEGG_ID>hsa:6256</KEGG_ID>
  <Orthology_ID>K08524</Orthology_ID>
  <EBI_ID>EBI-78598</EBI_ID>
  <Function_Summary>Receptor for retinoic acid. Retinoic acid receptors bind as heterodimers to their target response elements in response to their ligands, all-trans or 9-cis retinoic acid, and regulate gene expression in various biological processes. The RAR/RXR heterodimers bind to the retinoic acid response elements (RARE) composed of tandem 5'-AGGTCA-3' sites known as DR1-DR5. The high affinity ligand for RXRs is 9-cis retinoic acid. RXRA serves as a common heterodimeric partner for a number of nuclear receptors. The RXR/RAR heterodimers bind to the retinoic acid response elements (RARE) composed of tandem 5'-AGGTCA-3' sites known as DR1-DR5. In the absence of ligand, the RXR-RAR heterodimers associate with a multiprotein complex containing transcription corepressors that induce histone acetylation, chromatin condensation and transcriptional suppression. On ligand binding, the corepressors dissociate from the receptors and associate with the coactivators leading to transcriptional activation. The RXRA/PPARA heterodimer is required for PPARA transcriptional activity on fatty acid oxidation genes such as ACOX1 and the P450 system genes.</Function_Summary>
  <Pfam_ID>PF00104:Hormone_recep@@PF11825:Nuc_recep-AF1@@PF00105:zf-C4</Pfam_ID>
  <Allosteric_Activator_Count>2</Allosteric_Activator_Count>
  <Allosteric_Inhibitor_Count>1</Allosteric_Inhibitor_Count>
  <Allosteric_Regulator_Count>8</Allosteric_Regulator_Count>
  <Alias_List>
      <Alias>Retinoid X receptor alpha</Alias>
      <Alias>Nuclear receptor subfamily 2 group B member 1</Alias>
  </Alias_List>
  <Function_List>
    <Funtion>
      <Detail>Interacting selectively and non-covalently with any enzyme.</Detail>
      <Keyword>Enzyme binding</Keyword>
      <Ontology_ID>GO:0019899</Ontology_ID>
    </Funtion>
    <Funtion>
      <Detail>Interacting selectively with a retinoic acid-responsive element, a variable direct repeat of the sequence PuGGTCA spaced by five nucleotides (DR5) found in the promoters of retinoic acid-responsive genes, to which retinoic acid receptors bind.</Detail>
      <Keyword>Retinoic acid-responsive element binding</Keyword>
      <Ontology_ID>GO:0044323</Ontology_ID>
    </Funtion>
    <Funtion>
      <Detail>Interacting selectively and non-covalently with any metal ion.</Detail>
      <Keyword>Metal ion binding</Keyword>
      <Ontology_ID>GO:0046872</Ontology_ID>
    </Funtion>
    <Funtion>
      <Detail>Interacting selectively and non-covalently with zinc (Zn) ions.</Detail>
      <Keyword>Zinc ion binding</Keyword>
      <Ontology_ID>GO:0008270</Ontology_ID>
    </Funtion>
    <Funtion>
      <Detail>Any molecular function by which a gene product interacts selectively with DNA (deoxyribonucleic acid).</Detail>
      <Keyword>DNA binding</Keyword>
      <Ontology_ID>GO:0003677</Ontology_ID>
    </Funtion>
    <Funtion>
      <Detail>Combining with an extracellular or intracellular messenger to initiate a change in cell activity.</Detail>
      <Keyword>Receptor activity</Keyword>
      <Ontology_ID>GO:0004872</Ontology_ID>
    </Funtion>
    <Funtion>
      <Detail>Interacting selectively and non-covalently with DNA of a specific nucleotide composition, e.g. GC-rich DNA binding, or with a specific sequence motif or type of DNA e.g. promotor binding or rDNA binding.</Detail>
      <Keyword>Sequence-specific DNA binding</Keyword>
      <Ontology_ID>GO:0043565</Ontology_ID>
    </Funtion>
    <Funtion>
      <Detail>Interacting selectively and non-covalently with the vitamin D receptor, a nuclear receptor that mediates the action of vitamin D by binding DNA and controlling the transcription of hormone-sensitive genes.</Detail>
      <Keyword>Vitamin D receptor binding</Keyword>
      <Ontology_ID>GO:0042809</Ontology_ID>
    </Funtion>
    <Funtion>
      <Detail>Interacting selectively and non-covalently with a activating transcription factor and also with the basal transcription machinery in order to increase the frequency, rate or extent of transcription. Cofactors generally do not bind DNA, but rather mediate protein-protein interactions between activating transcription factors and the basal transcription machinery.</Detail>
      <Keyword>Transcription coactivator activity</Keyword>
      <Ontology_ID>GO:0003713</Ontology_ID>
    </Funtion>
    <Funtion>
      <Detail>Combining with 9-cis retinoic acid to initiate a change in cell activity.</Detail>
      <Keyword>Retinoid-X receptor activity</Keyword>
      <Ontology_ID>GO:0004886</Ontology_ID>
    </Funtion>
    <Funtion>
      <Detail>Combining with a steroid hormone to initiate a change in cell activity.</Detail>
      <Keyword>Steroid hormone receptor activity</Keyword>
      <Ontology_ID>GO:0003707</Ontology_ID>
    </Funtion>
    <Funtion>
      <Detail>Interacting selectively and non-covalently with a nonidentical protein to form a heterodimer.</Detail>
      <Keyword>Protein heterodimerization activity</Keyword>
      <Ontology_ID>GO:0046982</Ontology_ID>
    </Funtion>
  </Function_List>
  <Mutation_List>
    <Muntion>
      <Position>327</Position>
      <Original>Ala</Original>
      <Variation>Ser</Variation>
    </Muntion>
    <Muntion>
      <Position>261</Position>
      <Original>Pro</Original>
      <Variation>Leu</Variation>
    </Muntion>
    <Muntion>
      <Position>336</Position>
      <Original>Ser</Original>
      <Variation>Ile</Variation>
    </Muntion>
    <Muntion>
      <Position>398</Position>
      <Original>Ala</Original>
      <Variation>Val</Variation>
    </Muntion>
  </Mutation_List>
  <BioProcess_List>
    <BioProcess>
      <Detail>Any process that stops, prevents, or reduces the frequency, rate or extent of transcription from an RNA polymerase II promoter.</Detail>
      <Keyword>Negative regulation of transcription from RNA polymerase II promoter</Keyword>
      <Ontology_ID>GO:0000122</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>The cellular synthesis of either RNA on a template of DNA or DNA on a template of RNA.</Detail>
      <Keyword>Transcription</Keyword>
      <Ontology_ID>GO:0006350</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Interactions, directly with the host cell macromolecular machinery, to allow virus replication.</Detail>
      <Keyword>Virus-host interaction</Keyword>
      <Ontology_ID>GO:0019048</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>A change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a retinoic acid stimulus.</Detail>
      <Keyword>Response to retinoic acid</Keyword>
      <Ontology_ID>GO:0032526</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Any process that modulates the frequency, rate or extent of the synthesis of either RNA on a template of DNA or DNA on a template of RNA.</Detail>
      <Keyword>Regulation of transcription</Keyword>
      <Ontology_ID>GO:0045449</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>The chemical reactions and pathways involving vitamins. Vitamin is a general term for a number of unrelated organic substances that occur in many foods in small amounts and that are necessary in trace amounts for the normal metabolic functioning of the body. Vitamins may be water-soluble or fat-soluble and usually serve as components of coenzyme systems.</Detail>
      <Keyword>Vitamin metabolic process</Keyword>
      <Ontology_ID>GO:0006766</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Any process involved in the assembly of the RNA polymerase II preinitiation complex (PIC) at an RNA polymerase II promoter region of a DNA template, resulting in the subsequent synthesis of RNA from that promoter. The initiation phase includes PIC assembly and the formation of the first few bonds in the RNA chain, including abortive initiation, which occurs when the first few nucleotides are repeatedly synthesized and then released. Promoter clearance, or release, is the transition between the initiation and elongation phases of transcription.</Detail>
      <Keyword>Transcription initiation from RNA polymerase II promoter</Keyword>
      <Ontology_ID>GO:0006367</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>The chemical reactions and pathways involving cholesterol, cholest-5-en-3 beta-ol, the principal sterol of vertebrates and the precursor of many steroids, including bile acids and steroid hormones. It is a component of the plasma membrane lipid bilayer and of plasma lipoproteins and can be found in all animal tissues.</Detail>
      <Keyword>Cholesterol metabolic process</Keyword>
      <Ontology_ID>GO:0008203</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Any process in which an organism has an effect on an organism of a different species.</Detail>
      <Keyword>Interspecies interaction between organisms</Keyword>
      <Ontology_ID>GO:0044419</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Any process that activates or increases the frequency, rate or extent of transcription from the RNA polymerase II promoter.</Detail>
      <Keyword>Positive regulation of transcription from RNA polymerase II promoter</Keyword>
      <Ontology_ID>GO:0045944</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>The series of molecular signals initiated by binding of a ligand to any of the peroxisome proliferator activated receptors (alpha, beta or gamma) in the nuclear membrane, and ending with the initiation or termination of the transcription of target genes.</Detail>
      <Keyword>Peroxisome proliferator activated receptor signaling pathway</Keyword>
      <Ontology_ID>GO:0035357</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>The chemical reactions and pathways involving lipids, as carried out by individual cells.</Detail>
      <Keyword>Cellular lipid metabolic process</Keyword>
      <Ontology_ID>GO:0044255</Ontology_ID>
    </BioProcess>
  </BioProcess_List>
  <PTM_List>
    <PTM>
      <Position>260</Position>
      <PTM_Type>Phosphoserine</PTM_Type>
    </PTM>
    <PTM>
      <Position>27</Position>
      <PTM_Type>Phosphoserine</PTM_Type>
    </PTM>
    <PTM>
      <Position>56</Position>
      <PTM_Type>Phosphoserine</PTM_Type>
    </PTM>
    <PTM>
      <Position>70</Position>
      <PTM_Type>Phosphoserine</PTM_Type>
    </PTM>
    <PTM>
      <Position>82</Position>
      <PTM_Type>Phosphothreonine</PTM_Type>
    </PTM>
    <PTM>
      <Position>21</Position>
      <PTM_Type>Phosphoserine</PTM_Type>
    </PTM>
  </PTM_List>
  <Molecule_Seq>
    <Protein_Seq>MDTKHFLPLDFSTQVNSSLTSPTGRGSMAAPSLHPSLGPGIGSPGQLHSPISTLSSPINGMGPPFSVISSPMGPHSMSVPTTPTLGFSTGSPQLSSPMNPVSSSEDIKPPLGLNGVLKVPAHPSGNMASFTKHICAICGDRSSGKHYGVYSCEGCKGFFKRTVRKDLTYTCRDNKDCLIDKRQRNRCQYCRYQKCLAMGMKREAVQEERQRGKDRNENEVESTSSANEDMPVERILEAELAVEPKTETYVEANMGLNPSSPNDPVTNICQAADKQLFTLVEWAKRIPHFSELPLDDQVILLRAGWNELLIASFSHRSIAVKDGILLATGLHVHRNSAHSAGVGAIFDRVLTELVSKMRDMQMDKTELGCLRAIVLFNPDSKGLSNPAEVEALREKVYASLEAYCKHKYPEQPGRFAKLLLRLPALRSIGLKCLEHLFFFKLIGDTPIDTFLMEMLEAPHQMT</Protein_Seq>
    <DNA_Seq>GCGACTTTTGCAACAACTCGCCGCGCCGCGGCCTCCGCGCGCCGCCGCCGCCACCGCAGCCGCCGGCTCCCCGCCGCCCGGGCCCGGGCCGGCCGCGCCGGGGGCCGCCGCGCCCGCCGCCCGCTGCCTGCGCCGCCGGCCGGGCATGAGTTAGTCGCAGACATGGACACCAAACATTTCCTGCCGCTCGATTTCTCCACCCAGGTGAACTCCTCCCTCACCTCCCCGACGGGGCGAGGCTCCATGGCTGCCCCCTCGCTGCACCCGTCCCTGGGGCCTGGCATCGGCTCCCCGGGACAGCTGCATTCTCCCATCAGCACCCTGAGCTCCCCCATCAACGGCATGGGCCCGCCTTTCTCGGTCATCAGCTCCCCCATGGGCCCCCACTCCATGTCGGTGCCCACCACACCCACCCTGGGCTTCAGCACTGGCAGCCCCCAGCTCAGCTCACCTATGAACCCCGTCAGCAGCAGCGAGGACATCAAGCCCCCCCTGGGCCTCAATGGCGTCCTCAAGGTCCCCGCCCACCCCTCAGGAAACATGGCTTCCTTCACCAAGCACATCTGCGCCATCTGCGGGGACCGCTCCTCAGGCAAGCACTATGGAGTGTACAGCTGCGAGGGGTGCAAGGGCTTCTTCAAGCGGACGGTGCGCAAGGACCTGACCTACACCTGCCGCGACAACAAGGACTGCCTGATTGACAAGCGGCAGCGGAACCGGTGCCAGTACTGCCGCTACCAGAAGTGCCTGGCCATGGGCATGAAGCGGGAAGCCGTGCAGGAGGAGCGGCAGCGTGGCAAGGACCGGAACGAGAATGAGGTGGAGTCGACCAGCAGCGCCAACGAGGACATGCCGGTGGAGAGGATCCTGGAGGCTGAGCTGGCCGTGGAGCCCAAGACCGAGACCTACGTGGAGGCAAACATGGGGCTGAACCCCAGCTCGCCGAACGACCCTGTCACCAACATTTGCCAAGCAGCCGACAAACAGCTTTTCACCCTGGTGGAGTGGGCCAAGCGGATCCCACACTTCTCAGAGCTGCCCCTGGACGACCAGGTCATCCTGCTGCGGGCAGGCTGGAATGAGCTGCTCATCGCCTCCTTCTCCCACCGCTCCATCGCCGTGAAGGACGGGATCCTCCTGGCCACCGGGCTGCACGTCCACCGGAACAGCGCCCACAGCGCAGGGGTGGGCGCCATCTTTGACAGGGTGCTGACGGAGCTTGTGTCCAAGATGCGGGACATGCAGATGGACAAGACGGAGCTGGGCTGCCTGCGCGCCATCGTCCTCTTTAACCCTGACTCCAAGGGGCTCTCGAACCCGGCCGAGGTGGAGGCGCTGAGGGAGAAGGTCTATGCGTCCTTGGAGGCCTACTGCAAGCACAAGTACCCAGAGCAGCCGGGAAGGTTCGCTAAGCTCTTGCTCCGCCTGCCGGCTCTGCGCTCCATCGGGCTCAAATGCCTGGAACATCTCTTCTTCTTCAAGCTCATCGGGGACACACCCATTGACACCTTCCTTATGGAGATGCTGGAGGCGCCGCACCAAATGACTTAGGCCTGCGGGCCCATCCTTTGTGCCCACCCGTTCTGGCCACCCTGCCTGGACGCCAGCTGTTCTTCTCAGCCTGAGCCCTGTCCCTGCCCTTCTCTGCCTGGCCTGTTTGGACTTTGGGGCACAGCCTGTCACTGCTCTGCCTAAGAGATGTGTTGTCACCCTCCTTATTTCTGTTACTACTTGTCTGTGGCCCAGGGCAGTGGCTTTCCTGAGGCAGCAGCCTTCGTGGCAAGAACTAGCGTGAGCCCAGCCAGGCGCCTCCCCACCGGGCTCTCAGGACACCCTGCCACACCCCACGGGGCTTGGGCGACTACAGGGTCTTCGGGCCCCAGCCCTGGAGCTGCAGGAGTTGGGAACGGGGCTTTTGTTTCCGTTGCTGTTTATCGATGCTGGTTTTCAGAATTCCTGTGTGGCCCTCCTGTCTGGAGTGACATCTTCATCTGCTCTGAATACTGGTGCCCAGCCAGCCCGTGACAGCTTCCCCCTAATCAGGAGGGGACAGCTGGGGGCGCAAGCTGGTGTGTCATCAGCAAAGACCTCAGCCGCCTCGGGGATGAGAGGGGACTCGTGGGGCAAGCAAGCTGCCCTGTGCTCTGAGTGAGGGGGAAGGTAGCCCCTTTTTCCAAAGATAACTCACAGTTTTGCCCTCGAGCCAATGAGAACATGAGCTGCCCTCTGTGCAAGGTTTCGGGGCCACCTCCAGGCTGCAGGGGCGGGTCACTCACCCCCCTGTTTTCTCTCTGCCTTGGTGTTCTGGTTTCAGACTCCCGACTCCCCGTTCAGACCAGAGTGCCCCGGCCCCTCCCCAGCCTGAGTCTTCTCCTTGCTCTGCGGGGTGGGCTGAGGCTTGTCCTTGTTTCCTGCAGGGCTGGCCCTGGCTCGGGCAGGGTGGGGCATCACCACCTCACTGGCCTTGCTGGAGGCACAGGGCTCTGCGGACCTGCAGCCATCTGTGAGGCCCGCGGGGATGGGAGGGGAGGAGGGTGGCCTGTTGGTTTCCCTCAGAGGGGGCAGGTGGCCTGGAGAGAGAGGGGCTCAGGAACTGGGAGCCTCGTGGGTGGGGCAGATGCTCCGCGGCCTGGAGTGGCTCTGCCGGGGCATTGGTGGGACCCCTGCTCAGGCCTTCTCTCTGGCTGCCAGTTGTGTCTAAAAGACTCTTGGAATCTGAGAACCCGGAGTCGCAGCGCCCTCGGGCCTGGGCCACACGCAGGCCCTGGTGGGACCACCCAGCCTGGTATTGTCCACGGACAGCGTTGTTCACCCAGAGCCTTACTTGGGAGCCTCACTGAACGCCTGCTCTGGTTGAAGGTGGGGTGGGGGCGGGGCTTGGGGCCTCCCTGGCTCAGCCCAGTGCGGCCTGGCGCTCCTCCCGCAGGCTCTGCCCCCGGGCTCCGGTGGTGCGGGGCCCTCTCAGGTTGAACTCGCCTCTTTTGCACTGGAAGGCCCTCCCTTTGGCCTGAGTACTTTTCCCGTTCACGCCTCAGTCCCGTGGACCCAGCCTTTGTCAGTGGCAGGTGCCTGAACAGAGGGTGGATGGGGGGGATACCGGAGGGGGTCTTGTCTTCCCAGCCGCAGTCTAGGAATGATGCGGGGGGGTGGACGCCTTCTCCATAGTCTTTCCCCACCTGGAGCAGGGGCTTCCTCAGTGGTGAGGGGAGCTGCCTACAGGTTGGACCGGGAGGCAGTGGCTTGGAGAGGCAGCTTTCCAGCCTTGGTGGGGAAGAAAGTGTCCATTCTTTGCCTTCCTGGAGCTCCCAGCCAGAGCTGAGCTTAGGCACCCGAGTGGAGCCTGCAGCTGAGTCTGTGCCCGAGACAGGCTGTCAGAGATTCCAGAAGCCTCTCCTCCCCGCCGCCCTCCACCCCTGCCTTTCAGCGTTGTGGATCCCTAGAGGTGGCCCCCTGCCCGATCCACCGTCCTGAGGCAGAGTGTTGAGCCTCATACCTGTACCAGGTCCCCGGCCAGCTGGGCCCCTCCCAGGCACTGCCAGGAAGCCCCAGCTGCCCCTGGCGGGTGTGGTGGAAATGGCAGGAGGGTGCAGGTACTCTTGGGGCCCCAGCGGTGGGAGTGCAAAAGACCCAACGCCAACACCTGGTGCCTTCTGCAGCCAGCGCCCACCCATCCGTGCCCGGACCCTTGGGAATGCCCGCGGCTCCAGAGGAAAAAGCCCAGGGACGGGGCCTCCGTTGCGGGGGGTCGGCTGCTTCTTGGGAACTTTGTCGTTTCCGGCGCTGGCTGGCTGGCTGGCTGGCTGTAAAGCACTGAAGCCCCCCGGCCGCCAACCCCTGAAAGCAGAACCTGGCCTCCCTGGCCACAGCAGCCTTACCCACCGCTCTACGTGTCCCGGGCACTTCCCGCAGCCTTCCCGTCCCTTTCTCATCGGCCTTGTAGTTGTACAGTGCTGTTGGTTTGAAAAGGTGATGTGTGGGGAGTGCGGCTCATCACTGAGTAGAGAGGTAGAATTTCTATTTAACCAGACCTGTAGTAGTATTACCAATCCAGTTCAATTAAGGTGATTTTTTGTAATTATTATTATTTTGGTGGGACAATCTTTAATTTTCTAAAGATAGCACTAACATCAGCTCATTAGCCACCTGTGCCTGTCCCCGCCTTGGCCCGGCTGGATGAAGCGGCTTCCCCGCAGGGCCCCCACTTCCCAGTGGCTGCTTCCTGGGGACCCAGGGCACCCCGGCACCTTCAGGCACGCTCCTCAGCTGGTCACCTCCCGGCTTTGCCGTTCAGATGGGGCTCCTGAGGCTCAGGAGTGAAGATGCCACAGAGCCGGGCTCCCCTAGGCTGCGTCGGGCATGCTTGGAAGCTGGCCTGCCAGGACCTTCCACCCTGGGGCCTGTGTCAGCCGCCGGCCCTCCGCACCCTGGAAGCACACGGCCTCTGGGAAGGACAGCCCTGACCTTCGGTTTTCCGAGCACGGTGTTTCCCAAGAATTCTGGGCTGGCGGCCTGGTGGCAGTGCTGGAGATGACCCCGAGCCCCTCCCCGTGGGGCACCCAGGAGGGCCCTGCCGGAATGTGCAGCCTGTGGGTAGTCGGCTGGTGTCCCTGTCGTGGAGCTGGGGTGCGTGATCTGGTGCTCGTCCACGCAGGTGTGTGGTGTAAACATGTATGTGCTGTACAGAGAGACGCGTGTGGAGAGAGCCGCACACCAGCGCCACCCAGGAAAGGCGGAGCGGTTACCAGTGTTTTGTGTTTATTTTTAATCAAGACGTTTCCCCTGTTTTCCTATAAATTTGCTTCGTGTAAGCAAGTACATAAGGACCCTCCTTTGGTGAAATCCGGGTTCGAATGAATATCTCAAGGCAGGAGATGCATCTATTTTAAGATGCTTTGGAGCAGACAGCTTTAGCCGTTCCCAATCCTTAGCAATGCCTTAGCTGGGACGCATAGCTAATACTTTAGAGAGGATGACAGATCCATAAAGAGAGTAAAGATAAGAGAAAATGTCTAAAGCATCTGGAAAGGTAAAAAAAAAAAATCTATTTTTGTACAAATGTAATTTTATCCCTCATGTATACTTGGATATGGCGGGGGGAGGGCTGGGACTGTTTCGTTTCTGCTTCTAGAGATTGAGGTGAAAGCTTCGTCCGAGAAACGCCAGGACAGACGATGGCAGAGGAGAGGGCTCCTGTGACGGCGGCGAGGCTTGGGAGGAAACCGCCGCAATGGGGGTGTCTTCCCTCGGGGCAGGAGGGTGGGCCTGAGGCTTTCAAGGGTTTTCTTCCCTTTCGAGTAATTTTTAAAGCCTTGCTCTGTTGTGTCCTGTTGCCGGCTCTGGCCTTCCTGTGACTGACTGTGAAGTGGCTTCTCCGTACGATTGTCTCTGAAACATCGTGGCCTCAGGTGCCAGGGTTTGATGGACAGTAGCATTAGAATTGTGGAAAAGGAACACGCAAAGGGAGAAGTGTGAGAGGAGAAACAAAATATGAGCGTTTAAAATACATCGCCATTCAGTTCGTTAAAAAAAAAAAAAAAAAAAAAAAAA</DNA_Seq>
  </Molecule_Seq>
  <Tissuelocal_List>
    <TissueLocal>
      <TissueLocal>Heart</TissueLocal>
    </TissueLocal>
    <TissueLocal>
      <TissueLocal>Lung</TissueLocal>
    </TissueLocal>
    <TissueLocal>
      <TissueLocal>Liver</TissueLocal>
    </TissueLocal>
    <TissueLocal>
      <TissueLocal>Kidney</TissueLocal>
    </TissueLocal>
  </Tissuelocal_List>
  <CellLocal_List>
    <AsdMacromoleculeCelllocal>
        <CellLocal>Nucleus</CellLocal>
      <Ontology_ID>GO:0005634</Ontology_ID>
    </AsdMacromoleculeCelllocal>
    <AsdMacromoleculeCelllocal>
        <CellLocal>Nucleoplasm</CellLocal>
      <Ontology_ID>GO:0005654</Ontology_ID>
    </AsdMacromoleculeCelllocal>
    <AsdMacromoleculeCelllocal>
        <CellLocal>Nuclear chromatin</CellLocal>
      <Ontology_ID>GO:0000790</Ontology_ID>
    </AsdMacromoleculeCelllocal>
  </CellLocal_List>
  <Gene>
    <Gene_Name>RXRA</Gene_Name>
    <Gene_Alias>NR2B1</Gene_Alias>
    <Gene_ID>6256</Gene_ID>
    <Genbank_ACCN>NM_002957</Genbank_ACCN>
    <Protein_ACCN>NP_002948</Protein_ACCN>
    <HGNC_ID>10477</HGNC_ID>
    <Gene_URL>http://www.ncbi.nlm.nih.gov/gene/6256</Gene_URL>
    <UCSC_ID>uc004cfb.2</UCSC_ID>
    <EMBL_ID>ENSG00000186350</EMBL_ID>
  </Gene>
  <PPI_List>
    <PPI>
      <Uniprot_ID>P10276</Uniprot_ID>
      <Gene_Name>RARA</Gene_Name>
      <EBI_ID>EBI-413374</EBI_ID>
      <PPI_EBI_URL>EBI-78598,EBI-413374</PPI_EBI_URL>
      <Experiment_Number>3</Experiment_Number>
    </PPI>
    <PPI>
      <Uniprot_ID>Q9JLI4</Uniprot_ID>
      <Gene_Name>Ncoa6</Gene_Name>
      <EBI_ID>EBI-286271</EBI_ID>
      <PPI_EBI_URL>EBI-78598,EBI-286271</PPI_EBI_URL>
      <Experiment_Number>2</Experiment_Number>
    </PPI>
    <PPI>
      <Uniprot_ID>P27986</Uniprot_ID>
      <Gene_Name>PIK3R1</Gene_Name>
      <EBI_ID>EBI-79464</EBI_ID>
      <PPI_EBI_URL>EBI-78598,EBI-79464</PPI_EBI_URL>
      <Experiment_Number>8</Experiment_Number>
    </PPI>
    <PPI>
      <Uniprot_ID>P42224</Uniprot_ID>
      <Gene_Name>STAT1</Gene_Name>
      <EBI_ID>EBI-1057697</EBI_ID>
      <PPI_EBI_URL>EBI-78598,EBI-1057697</PPI_EBI_URL>
      <Experiment_Number>2</Experiment_Number>
    </PPI>
  </PPI_List>
  <Disease_List>
    <Disease>
      <Disease_Name>X-Linked Adrenal Hypoplasia Congenita</Disease_Name>
      <Disease_Detail>X-Linked Adrenal Hypoplasia Congenita</Disease_Detail>
      <Disease_DB>XLN010</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/x_linked_adrenal_hypoplasia_congenita?search=RXRA#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Recessive Dystrophic Epidermolysis Bullosa</Disease_Name>
      <Disease_Detail>Recessive Dystrophic Epidermolysis Bullosa</Disease_Detail>
      <Disease_DB>RCS002</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/recessive_dystrophic_epidermolysis_bullosa?search=RXRA#related_genes</Disease_URL>
    </Disease>
  </Disease_List>
  <PDB_List>
    <PDB>
      <PDB_Title>Crystal structure of RXRalpha ligand binding domain in complex with triphenyltin and a coactivator fragment</PDB_Title>
      <PDB_ID>3KWY</PDB_ID>
      <Resolution>2.3</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3KWY</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>A structural view of nuclear hormone receptor: endocrine disruptor interactions.</PubMed_Title>
      <Author>le Maire, A., et al.</Author>
      <Journal>Cell.Mol.Life Sci.(2010)67:1219-1237</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/20063036?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Crystal Structure of Heterodimeric Ecdsyone receptor DNA binding complex</PDB_Title>
      <PDB_ID>1R0N</PDB_ID>
      <Resolution>2.6</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1R0N</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Structure of the heterodimeric Ecdysone Receptor DNA-binding complex</PubMed_Title>
      <Author>Devarakonda, S., et al.</Author>
      <Journal>Embo J.(2003)22:5827-5840</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/14592980?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>THE 2.5 ANGSTROM RESOLUTION CRYSTAL STRUCTURE OF THE RXRALPHA LIGAND BINDING DOMAIN IN TETRAMER IN THE ABSENCE OF LIGAND</PDB_Title>
      <PDB_ID>1G1U</PDB_ID>
      <Resolution>2.5</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1G1U</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Structural basis for autorepression of retinoid X receptor by tetramer formation and the AF-2 helix.</PubMed_Title>
      <Author>Gampe Jr., R.T., et al.</Author>
      <Journal>Genes Dev.(2000)14:2229-2241</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/10970886?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>humanRXR alpha &amp; mouse LXR alpha complexed with Retenoic acid and GSK2186</PDB_Title>
      <PDB_ID>3FAL</PDB_ID>
      <Resolution>2.36</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3FAL</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Structure-guided design of N-phenyl tertiary amines as transrepression-selective liver X receptor modulators with anti-inflammatory activity.</PubMed_Title>
      <Author>Chao, E.Y., et al.</Author>
      <Journal>J.Med.Chem.(2008)51:5758-5765</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/18800767?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Crystal structure of RXRalphaLBD complexed with the agonist magnolol</PDB_Title>
      <PDB_ID>3R5M</PDB_ID>
      <Resolution>2.8</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3R5M</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Molecular determinants of magnolol targeting both RXR(alpha) and PPAR(gamma).</PubMed_Title>
      <Author>Zhang, H., et al.</Author>
      <Journal>Plos One(2011)6:e28253-e28253</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/22140563?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Crystal Structure of Peroxisome Proliferator-Activated Receptor Gamma (PPARg) and Retinoic Acid Receptor Alpha (RXRa) in Complex with 9-cis Retinoic Acid, Co-activator Peptide, and a Partial Agonist</PDB_Title>
      <PDB_ID>3H0A</PDB_ID>
      <Resolution>2.1</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3H0A</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Identification of a PPARdelta agonist with partial agonistic activity on PPARgamma.</PubMed_Title>
      <Author>Connors, R.V., et al.</Author>
      <Journal>Bioorg.Med.Chem.Lett.(2009)19:3550-3554</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/19464171?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>LIGAND-BINDING DOMAIN OF THE HUMAN NUCLEAR RECEPTOR RXR-ALPHA</PDB_Title>
      <PDB_ID>1LBD</PDB_ID>
      <Resolution>2.7</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1LBD</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Crystal structure of the ligand-binding domain of the human nuclear receptor RXR-alpha.</PubMed_Title>
      <Author>Bourguet, W., et al.</Author>
      <Journal>Nature(1995)375:377-382</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/7760929?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Liver X-Receptor alpha Ligand Binding Domain with SB313987</PDB_Title>
      <PDB_ID>2ACL</PDB_ID>
      <Resolution>2.8</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=2ACL</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Discovery of substituted maleimides as liver x receptor agonists and determination of a ligand-bound crystal structure.</PubMed_Title>
      <Author>Jaye, M.C., et al.</Author>
      <Journal>J.Med.Chem.(2005)48:5419-5422</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/16107141?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>CRYSTAL STRUCTURE OF THE HUMAN RXR ALPHA LIGAND BINDING DOMAIN BOUND TO 9-CIS RETINOIC ACID</PDB_Title>
      <PDB_ID>1FBY</PDB_ID>
      <Resolution>2.25</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1FBY</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Crystal structure of the human RXRalpha ligand-binding domain bound to its natural ligand: 9-cis retinoic acid.</PubMed_Title>
      <Author>Egea, P.F., et al.</Author>
      <Journal>EMBO J.(2000)19:2592-2601</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/10835357?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Crystal Structure of Vitamin D Receptor and 9-cis Retinoic Acid Receptor DNA-Binding Domains Bound to a DR3 Response Element</PDB_Title>
      <PDB_ID>1YNW</PDB_ID>
      <Resolution>3.0</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1YNW</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Structural analysis of RXR-VDR interactions on DR3 DNA</PubMed_Title>
      <Author>Shaffer, P.L., et al.</Author>
      <Journal>J.Steroid Biochem.Mol.Biol.(2004)89-90:215-219</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/15225774?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Intact PPAR gamma - RXR alpha Nuclear Receptor Complex on DNA bound with Rosiglitazone, 9-cis Retinoic Acid and NCOA2 Peptide</PDB_Title>
      <PDB_ID>3DZY</PDB_ID>
      <Resolution>3.1</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3DZY</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Structure of the intact PPAR-gamma-RXR- nuclear receptor complex on DNA.</PubMed_Title>
      <Author>Chandra, V., et al.</Author>
      <Journal>Nature(2008)456:350-356</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/19043829?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Crystal structure of RXRalpha ligand-binding domain complexed with corepressor SMRT2 and antagonist rhein</PDB_Title>
      <PDB_ID>3R2A</PDB_ID>
      <Resolution>3.0</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3R2A</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Structural basis for retinoic x receptor repression on the tetramer.</PubMed_Title>
      <Author>Zhang, H., et al.</Author>
      <Journal>J.Biol.Chem.(2011)286:24593-24598</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/21613212?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Intact PPAR gamma - RXR alpha Nuclear Receptor Complex on DNA bound with BVT.13, 9-cis Retinoic Acid and NCOA2 Peptide</PDB_Title>
      <PDB_ID>3DZU</PDB_ID>
      <Resolution>3.2</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3DZU</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Structure of the intact PPAR-gamma-RXR- nuclear receptor complex on DNA.</PubMed_Title>
      <Author>Chandra, V., et al.</Author>
      <Journal>Nature(2008)456:350-356</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/19043829?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>The 2.3 Angstrom resolution crystal structure of the heterodimer of the human PPARgamma and RXRalpha ligand binding domains respectively bound with GW409544 and 9-cis retinoic acid and co-activator peptides.</PDB_Title>
      <PDB_ID>1K74</PDB_ID>
      <Resolution>2.3</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1K74</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Structural determinants of ligand binding selectivity between the peroxisome proliferator-activated receptors.</PubMed_Title>
      <Author>Xu, H.E., et al.</Author>
      <Journal>Proc.Natl.Acad.Sci.USA(2001)98:13919-13924</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/11698662?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>THE 2.0 ANGSTROM RESOLUTION CRYSTAL STRUCTURE OF THE RXRALPHA LIGAND BINDING DOMAIN TETRAMER IN THE PRESENCE OF A NON-ACTIVATING RETINOIC ACID ISOMER.</PDB_Title>
      <PDB_ID>1G5Y</PDB_ID>
      <Resolution>2.0</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1G5Y</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Structural basis for autorepression of retinoid X receptor by tetramer formation and the AF-2 helix.</PubMed_Title>
      <Author>Gampe Jr., R.T., et al.</Author>
      <Journal>Genes Dev.(2000)14:2229-2241</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/10970886?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>HIGH RESOLUTION SOLUTION STRUCTURE OF THE RETINOID X RECEPTOR DNA BINDING DOMAIN, NMR, 20 STRUCTURE</PDB_Title>
      <PDB_ID>1RXR</PDB_ID>
      <Resolution>-1.0</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1RXR</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>High-resolution solution structure of the retinoid X receptor DNA-binding domain.</PubMed_Title>
      <Author>Holmbeck, S.M., et al.</Author>
      <Journal>J.Mol.Biol.(1998)281:271-284</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/9698548?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Crystal Structure of the human RXR alpha ligand binding domain bound to the eicosanoid DHA (Docosa Hexaenoic Acid) and a coactivator peptide</PDB_Title>
      <PDB_ID>1MV9</PDB_ID>
      <Resolution>1.9</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1MV9</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Molecular Recognition of Agonist Ligands by RXRs</PubMed_Title>
      <Author>Egea, P.F., et al.</Author>
      <Journal>MOL.ENDOCRINOL.(2002)16:987-997</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/11981034?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>RETINOID X RECEPTOR-THYROID HORMONE RECEPTOR DNA-BINDING DOMAIN HETERODIMER BOUND TO THYROID RESPONSE ELEMENT DNA</PDB_Title>
      <PDB_ID>2NLL</PDB_ID>
      <Resolution>1.9</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=2NLL</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Structural determinants of nuclear receptor assembly on DNA direct repeats.</PubMed_Title>
      <Author>Rastinejad, F., et al.</Author>
      <Journal>Nature(1995)375:203-211</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/7746322?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Crystal Structure of a new rexinoid bound to the RXRalpha ligand binding doamin in the RXRalpha/PPARgamma heterodimer</PDB_Title>
      <PDB_ID>1RDT</PDB_ID>
      <Resolution>2.4</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1RDT</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Structure-based design of potent retinoid X receptor alpha agonists.</PubMed_Title>
      <Author>Haffner, C.D., et al.</Author>
      <Journal>J.Med.Chem.(2004)47:2010-2029</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/15056000?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Crystal structure of human retinoic X receptor alpha complexed with bigelovin and coactivator SRC-1</PDB_Title>
      <PDB_ID>3OZJ</PDB_ID>
      <Resolution>2.1</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3OZJ</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Structure basis of bigelovin as a selective RXR agonist with a distinct binding mode</PubMed_Title>
      <Author>Zhang, H., et al.</Author>
      <Journal>J.Mol.Biol.(2011)407:13-20</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/21262235?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Intact PPAR gamma - RXR alpha Nuclear Receptor Complex on DNA bound with GW9662, 9-cis Retinoic Acid and NCOA2 Peptide</PDB_Title>
      <PDB_ID>3E00</PDB_ID>
      <Resolution>3.1</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3E00</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Structure of the intact PPAR-gamma-RXR- nuclear receptor complex on DNA.</PubMed_Title>
      <Author>Chandra, V., et al.</Author>
      <Journal>Nature(2008)456:350-356</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/19043829?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>hRXRalpha &amp; mLXRalpha with an indole Pharmacophore, SB786875</PDB_Title>
      <PDB_ID>3FC6</PDB_ID>
      <Resolution>2.06</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3FC6</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Synthesis and SAR of potent LXR agonists containing an indole pharmacophore.</PubMed_Title>
      <Author>Washburn, D.G., et al.</Author>
      <Journal>Bioorg.Med.Chem.Lett.(2009)19:1097-1100</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/19167885?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Crystal structure of tetrameric RXRalpha-LBD</PDB_Title>
      <PDB_ID>3NSP</PDB_ID>
      <Resolution>2.9</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3NSP</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Danthron functions as a retinoic X receptor antagonist by stabilizing tetramers of the receptor.</PubMed_Title>
      <Author>Zhang, H., et al.</Author>
      <Journal>J.Biol.Chem.(2011)286:1868-1875</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/21084305?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>crystal structure of CAR/RXR heterodimer bound with SRC1 peptide, fatty acid, and 5b-pregnane-3,20-dione.</PDB_Title>
      <PDB_ID>1XV9</PDB_ID>
      <Resolution>2.7</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1XV9</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>A Structural Basis for Constitutive Activity in the Human CAR/RXRalpha Heterodimer.</PubMed_Title>
      <Author>Xu, R.X., et al.</Author>
      <Journal>Mol.Cell(2004)16:919-928</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/15610735?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Crystal structure of tetrameric RXRalpha-LBD complexed with antagonist danthron</PDB_Title>
      <PDB_ID>3NSQ</PDB_ID>
      <Resolution>2.6</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3NSQ</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Danthron functions as a retinoic X receptor antagonist by stabilizing tetramers of the receptor.</PubMed_Title>
      <Author>Zhang, H., et al.</Author>
      <Journal>J.Biol.Chem.(2011)286:1868-1875</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/21084305?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>THE 2.1 ANGSTROM RESOLUTION CRYSTAL STRUCTURE OF THE HETERODIMER OF THE HUMAN RXRALPHA AND PPARGAMMA LIGAND BINDING DOMAINS RESPECTIVELY BOUND WITH 9-CIS RETINOIC ACID AND GI262570 AND CO-ACTIVATOR PEPTIDES.</PDB_Title>
      <PDB_ID>1FM9</PDB_ID>
      <Resolution>2.1</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1FM9</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Asymmetry in the PPARgamma/RXRalpha crystal structure reveals the molecular basis of heterodimerization among nuclear receptors.</PubMed_Title>
      <Author>Gampe Jr., R.T., et al.</Author>
      <Journal>Mol.Cell(2000)5:545-555</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/10882139?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Crystal structure of the ligand binding domain of the retinoid X receptor alpha in complex with 3-(2'-ethoxy)-tetrahydronaphtyl cinnamic acid and a fragment of the coactivator TIF-2</PDB_Title>
      <PDB_ID>2P1U</PDB_ID>
      <Resolution>2.2</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=2P1U</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Modulators of the structural dynamics of the retinoid X receptor to reveal receptor function.</PubMed_Title>
      <Author>Nahoum, V., et al.</Author>
      <Journal>Proc.Natl.Acad.Sci.Usa(2007)104:17323-17328</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/17947383?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Crystal structure of the human RXR alpha ligand binding domain bound to the synthetic agonist compound BMS 649 and a coactivator peptide</PDB_Title>
      <PDB_ID>1MVC</PDB_ID>
      <Resolution>1.9</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1MVC</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Molecular Recognition of Agonist Ligands by RXRs</PubMed_Title>
      <Author>Egea, P.F., et al.</Author>
      <Journal>MOL.ENDOCRINOL.(2002)16:987-997</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/11981034?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Crystal Structure of the Retinoid X Receptor Ligand Binding Domain Bound to the Synthetic Agonist 3-[4-Hydroxy-3-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydronaphthalen-2-yl)-phenyl]acrylic Acid</PDB_Title>
      <PDB_ID>3FUG</PDB_ID>
      <Resolution>2.0</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3FUG</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Modulating retinoid X receptor with a series of (E)-3-[4-hydroxy-3-(3-alkoxy-5,5,8,8-tetramethyl-5,6,7,8-tetrahydronaphthalen-2-yl)phenyl]acrylic acids and their 4-alkoxy isomers.</PubMed_Title>
      <Author>Perez Santin, E., et al.</Author>
      <Journal>J.Med.Chem.(2009)52:3150-3158</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/19408900?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Crystal structure of the ligand binding domain of the retinoid X receptor alpha in complex with 3-(2'-propoxy)-tetrahydronaphtyl cinnamic acid and a fragment of the coactivator TIF-2</PDB_Title>
      <PDB_ID>2P1V</PDB_ID>
      <Resolution>2.2</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=2P1V</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Modulators of the structural dynamics of the retinoid X receptor to reveal receptor function.</PubMed_Title>
      <Author>Nahoum, V., et al.</Author>
      <Journal>Proc.Natl.Acad.Sci.Usa(2007)104:17323-17328</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/17947383?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Crystal structure of RXRalpha ligand-binding domain complexed with corepressor SMRT2</PDB_Title>
      <PDB_ID>3R29</PDB_ID>
      <Resolution>2.9</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3R29</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Structural basis for retinoic x receptor repression on the tetramer.</PubMed_Title>
      <Author>Zhang, H., et al.</Author>
      <Journal>J.Biol.Chem.(2011)286:24593-24598</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/21613212?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>crystal structure of CAR/RXR heterodimer bound with SRC1 peptide, fatty acid and CITCO</PDB_Title>
      <PDB_ID>1XVP</PDB_ID>
      <Resolution>2.6</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1XVP</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>A Structural Basis for Constitutive Activity in the Human CAR/RXRalpha Heterodimer.</PubMed_Title>
      <Author>Xu, R.X., et al.</Author>
      <Journal>Mol.Cell(2004)16:919-928</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/15610735?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Crystal structure of human retinoic X receptor alpha ligand-binding domain complexed with LX0278 and SRC1 peptide</PDB_Title>
      <PDB_ID>3PCU</PDB_ID>
      <Resolution>2.0</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3PCU</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>(+)-Rutamarin as a Dual Inducer of Both GLUT4 Translocation and Expression Efficiently Ameliorates Glucose Homeostasis in Insulin-Resistant Mice.</PubMed_Title>
      <Author>Zhang, Y., et al.</Author>
      <Journal>Plos One(2012)7:e31811-e31811</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/22384078?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Crystal structure of RXRalpha ligand binding domain in complex with tributyltin and a coactivator fragment</PDB_Title>
      <PDB_ID>3E94</PDB_ID>
      <Resolution>1.9</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3E94</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Activation of RXR-PPAR heterodimers by organotin environmental endocrine disruptors</PubMed_Title>
      <Author>le Maire, A., et al.</Author>
      <Journal>Embo Rep.(2009)10:367-373</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/19270714?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>CRYSTAL STRUCTURE at 1.9 ANGSTROEMS RESOLUTION OF THE HOMODIMER OF HUMAN RXR ALPHA LIGAND BINDING DOMAIN BOUND TO THE SYNTHETIC AGONIST COMPOUND BMS 649 AND A COACTIVATOR PEPTIDE</PDB_Title>
      <PDB_ID>1MZN</PDB_ID>
      <Resolution>1.9</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1MZN</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Molecular Recognition of Agonist Ligands by RXRs</PubMed_Title>
      <Author>Egea, P.F., et al.</Author>
      <Journal>MOL.ENDOCRINOL.(2002)16:987-997</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/11981034?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>STRUCTURE OF THE RXR/RAR DNA-BINDING DOMAIN HETERODIMER IN COMPLEX WITH THE RETINOIC ACID RESPONSE ELEMENT DR1</PDB_Title>
      <PDB_ID>1DSZ</PDB_ID>
      <Resolution>1.7</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1DSZ</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Structure of the RXR-RAR DNA-binding complex on the retinoic acid response element DR1.</PubMed_Title>
      <Author>Rastinejad, F., et al.</Author>
      <Journal>EMBO J.(2000)19:1045-1054</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/10698945?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Crystal structure of the mouse CAR/RXR LBD heterodimer bound to TCPOBOP and 9cRA and a TIF2 peptide containg the third LXXLL motifs</PDB_Title>
      <PDB_ID>1XLS</PDB_ID>
      <Resolution>2.96</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1XLS</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>The nuclear xenobiotic receptor CAR: structural determinants of constitutive activation and heterodimerization.</PubMed_Title>
      <Author>Suino, K., et al.</Author>
      <Journal>Mol.Cell(2004)16:893-905</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/15610733?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>STRUCTURE AND MECHANISM OF THE HOMODIMERIC ASSEMBLY OF THE RXR ON DNA</PDB_Title>
      <PDB_ID>1BY4</PDB_ID>
      <Resolution>2.1</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1BY4</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Structural basis of RXR-DNA interactions.</PubMed_Title>
      <Author>Zhao, Q., et al.</Author>
      <Journal>J.Mol.Biol.(2000)296:509-520</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/10669605?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Crystal structure of human Retinoid X Receptor alpha-ligand binding domain complex with 9-cis retinoic acid and the coactivator peptide GRIP-1</PDB_Title>
      <PDB_ID>3OAP</PDB_ID>
      <Resolution>2.05</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3OAP</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Structure, Energetics and Dynamics of Binding Coactivator Peptide to Human Retinoid X Receptor Alpha Ligand Binding Domain Complex with 9-cis-Retinoic Acid.</PubMed_Title>
    </PDB>
    <PDB>
      <PDB_Title>THE 2.1 ANGSTROM RESOLUTION CRYSTAL STRUCTURE OF THE HETERODIMER OF THE HUMAN RXRALPHA AND PPARGAMMA LIGAND BINDING DOMAINS RESPECTIVELY BOUND WITH 9-CIS RETINOIC ACID AND ROSIGLITAZONE AND CO-ACTIVATOR PEPTIDES.</PDB_Title>
      <PDB_ID>1FM6</PDB_ID>
      <Resolution>2.1</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1FM6</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Asymmetry in the PPARgamma/RXRalpha crystal structure reveals the molecular basis of heterodimerization among nuclear receptors.</PubMed_Title>
      <Author>Gampe Jr., R.T., et al.</Author>
      <Journal>Mol.Cell(2000)5:545-555</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/10882139?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Crystal structure of the ligand binding domain of the retinoid X receptor alpha in complex with 3-(2'-methoxy)-tetrahydronaphtyl cinnamic acid and a fragment of the coactivator TIF-2</PDB_Title>
      <PDB_ID>2P1T</PDB_ID>
      <Resolution>1.8</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=2P1T</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Modulators of the structural dynamics of the retinoid X receptor to reveal receptor function.</PubMed_Title>
      <Author>Nahoum, V., et al.</Author>
      <Journal>Proc.Natl.Acad.Sci.Usa(2007)104:17323-17328</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/17947383?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Crystal structure of the human RXR alpha ligand binding domain bound to a synthetic agonist compound and a coactivator peptide</PDB_Title>
      <PDB_ID>2ZXZ</PDB_ID>
      <Resolution>3.0</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=2ZXZ</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Silicon analogues of the RXR-selective retinoid agonist SR11237 (BMS649): chemistry and biology</PubMed_Title>
      <Author>Lippert, W.P., et al.</Author>
      <Journal>Chemmedchem(2009)4:1143-1152</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/19496083?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Crystal structure of the human RXR alpha ligand binding domain bound to a synthetic agonist compound and a coactivator peptide</PDB_Title>
      <PDB_ID>2ZY0</PDB_ID>
      <Resolution>2.9</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=2ZY0</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Silicon analogues of the RXR-selective retinoid agonist SR11237 (BMS649): chemistry and biology</PubMed_Title>
      <Author>Lippert, W.P., et al.</Author>
      <Journal>Chemmedchem(2009)4:1143-1152</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/19496083?dopt=Abstract</PubMed_ID>
    </PDB>
  </PDB_List>
  <Network_List>
    <Network>
      <Pathway_ID>ko03320</Pathway_ID>
      <Pathway_Title>PPAR signaling pathway</Pathway_Title>
      <Pathway_Class>Organismal Systems</Pathway_Class>
      <Pathway_Subclass>Endocrine system</Pathway_Subclass>
    </Network>
    <Network>
      <Pathway_ID>ko04920</Pathway_ID>
      <Pathway_Title>Adipocytokine signaling pathway</Pathway_Title>
      <Pathway_Class>Organismal Systems</Pathway_Class>
      <Pathway_Subclass>Endocrine system</Pathway_Subclass>
    </Network>
    <Network>
      <Pathway_ID>ko04976</Pathway_ID>
      <Pathway_Title>Bile secretion</Pathway_Title>
      <Pathway_Class>Organismal Systems</Pathway_Class>
      <Pathway_Subclass>Digestive system</Pathway_Subclass>
    </Network>
    <Network>
      <Pathway_ID>ko05222</Pathway_ID>
      <Pathway_Title>Small cell lung cancer</Pathway_Title>
      <Pathway_Class>Human Diseases</Pathway_Class>
      <Pathway_Subclass>Cancers</Pathway_Subclass>
    </Network>
    <Network>
      <Pathway_ID>ko05200</Pathway_ID>
      <Pathway_Title>Pathways in cancer</Pathway_Title>
      <Pathway_Class>Human Diseases</Pathway_Class>
      <Pathway_Subclass>Cancers</Pathway_Subclass>
    </Network>
    <Network>
      <Pathway_ID>ko03320</Pathway_ID>
      <Pathway_Title>PPAR signaling pathway</Pathway_Title>
      <Pathway_Class>Organismal Systems</Pathway_Class>
      <Pathway_Subclass>Endocrine system</Pathway_Subclass>
    </Network>
    <Network>
      <Pathway_ID>ko04919</Pathway_ID>
      <Pathway_Title>Thyroid hormone signaling pathway</Pathway_Title>
      <Pathway_Class>Organismal Systems</Pathway_Class>
      <Pathway_Subclass>Endocrine system</Pathway_Subclass>
    </Network>
    <Network>
      <Pathway_ID>ko04932</Pathway_ID>
      <Pathway_Title>Non-alcoholic fatty liver disease (NAFLD)</Pathway_Title>
      <Pathway_Class>Human Diseases</Pathway_Class>
      <Pathway_Subclass>Endocrine and metabolic diseases</Pathway_Subclass>
    </Network>
    <Network>
      <Pathway_ID>ko03320</Pathway_ID>
      <Pathway_Title>PPAR signaling pathway</Pathway_Title>
      <Pathway_Class>Organismal Systems</Pathway_Class>
      <Pathway_Subclass>Endocrine system</Pathway_Subclass>
    </Network>
    <Network>
      <Pathway_ID>ko05200</Pathway_ID>
      <Pathway_Title>Pathways in cancer</Pathway_Title>
      <Pathway_Class>Human Diseases</Pathway_Class>
      <Pathway_Subclass>Cancers</Pathway_Subclass>
    </Network>
    <Network>
      <Pathway_ID>ko05223</Pathway_ID>
      <Pathway_Title>Non-small cell lung cancer</Pathway_Title>
      <Pathway_Class>Human Diseases</Pathway_Class>
      <Pathway_Subclass>Cancers</Pathway_Subclass>
    </Network>
    <Network>
      <Pathway_ID>ko04151</Pathway_ID>
      <Pathway_Title>PI3K-Akt signaling pathway</Pathway_Title>
      <Pathway_Class>Environmental Information Processing</Pathway_Class>
      <Pathway_Subclass>Signal transduction</Pathway_Subclass>
    </Network>
    <Network>
      <Pathway_ID>ko05216</Pathway_ID>
      <Pathway_Title>Thyroid cancer</Pathway_Title>
      <Pathway_Class>Human Diseases</Pathway_Class>
      <Pathway_Subclass>Cancers</Pathway_Subclass>
    </Network>
    <Network>
      <Pathway_ID>ko05160</Pathway_ID>
      <Pathway_Title>Hepatitis C</Pathway_Title>
      <Pathway_Class>Human Diseases</Pathway_Class>
      <Pathway_Subclass>Infectious diseases</Pathway_Subclass>
    </Network>
    <Network>
      <Pathway_ID>ko04919</Pathway_ID>
      <Pathway_Title>Thyroid hormone signaling pathway</Pathway_Title>
      <Pathway_Class>Organismal Systems</Pathway_Class>
      <Pathway_Subclass>Endocrine system</Pathway_Subclass>
    </Network>
    <Network>
      <Pathway_ID>ko04919</Pathway_ID>
      <Pathway_Title>Thyroid hormone signaling pathway</Pathway_Title>
      <Pathway_Class>Organismal Systems</Pathway_Class>
      <Pathway_Subclass>Endocrine system</Pathway_Subclass>
    </Network>
    <Network>
      <Pathway_ID>ko05202</Pathway_ID>
      <Pathway_Title>Transcriptional misregulation in cancer</Pathway_Title>
      <Pathway_Class>Human Diseases</Pathway_Class>
      <Pathway_Subclass>Cancers</Pathway_Subclass>
    </Network>
    <Network>
      <Pathway_ID>ko04932</Pathway_ID>
      <Pathway_Title>Non-alcoholic fatty liver disease (NAFLD)</Pathway_Title>
      <Pathway_Class>Human Diseases</Pathway_Class>
      <Pathway_Subclass>Endocrine and metabolic diseases</Pathway_Subclass>
    </Network>
    <Network>
      <Pathway_ID>ko05160</Pathway_ID>
      <Pathway_Title>Hepatitis C</Pathway_Title>
      <Pathway_Class>Human Diseases</Pathway_Class>
      <Pathway_Subclass>Infectious diseases</Pathway_Subclass>
    </Network>
    <Network>
      <Pathway_ID>ko04976</Pathway_ID>
      <Pathway_Title>Bile secretion</Pathway_Title>
      <Pathway_Class>Organismal Systems</Pathway_Class>
      <Pathway_Subclass>Digestive system</Pathway_Subclass>
    </Network>
  </Network_List>
  <Fold>
    <SCOP_Class>Small proteins</SCOP_Class>
    <SCOP_URL>http://scop.mrc-lmb.cam.ac.uk/scop/data/scop.b.h.fe.b.c.b.html</SCOP_URL>
    <CATH_Class>Class 3: Mixed Alpha-Beta</CATH_Class>
    <CATH_URL>http://www.cathdb.info/pdb/1by4</CATH_URL>
  </Fold>
  <AllostericSite_List>
    <AllostericSite>
      <Site_Type>Ligand-induced conformational change</Site_Type>
    </AllostericSite>
  </AllostericSite_List>
  <Allosteric_Pathway>
    <Method>Statistical coupling analysis (SCA), mutations.</Method>
    <Verified__Residue>E239, W282, A283, K284, F289, Q297, L301, R302, W305, E307, R334, D363, C369, D379, L383, R393, L419, R426, K440, F450</Verified__Residue>
    <PubMed_Title>Shulman AI, et al. Cell. 2004,116(3):417-429.</PubMed_Title>
    <PubMed_ID>15016376</PubMed_ID>
    <is__ref__img>Yes</is__ref__img>
    <is__display>No</is__display>
    <in__pathway__browse>Yes</in__pathway__browse>
  </Allosteric_Pathway>
  <Modulator_List>
    <Modulator>
      <ASD_ID>ASD05660001</ASD_ID>
      <Modulator_Feature>Regulator</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD05660002</ASD_ID>
      <Modulator_Feature>Regulator</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD05660003</ASD_ID>
      <Modulator_Feature>Regulator</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD05660004</ASD_ID>
      <Modulator_Feature>Regulator</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD05660005</ASD_ID>
      <Modulator_Feature>Regulator</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD05660006</ASD_ID>
      <Modulator_Feature>Regulator</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD05660007</ASD_ID>
      <Modulator_Feature>Regulator</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD05660008</ASD_ID>
      <Modulator_Feature>Regulator</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD05660009</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD05663001</ASD_ID>
      <Modulator_Feature>Activator</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD05663002</ASD_ID>
      <Modulator_Feature>Activator</Modulator_Feature>
    </Modulator>
  </Modulator_List>
  <Create_Date>2012-06-20</Create_Date>
</Organism_Record>